Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

387 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
Amrane K, Geier M, Corre R, Léna H, Léveiller G, Gadby F, Lamy R, Bizec JL, Goarant E, Robinet G, Gouva S, Quere G, Abgral R, Schick U, Bernier C, Chouaid C, Descourt R. Amrane K, et al. Among authors: chouaid c. Cancer Med. 2020 Apr;9(7):2309-2316. doi: 10.1002/cam4.2806. Epub 2020 Feb 5. Cancer Med. 2020. PMID: 32022459 Free PMC article. Clinical Trial.
An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.
LeCaer H, Barlesi F, Robinet G, Fournel P, Geriniere L, Bombaron P, Falchero L, Auliac JB, Crequit J, Chouaid C. LeCaer H, et al. Among authors: chouaid c. Lung Cancer. 2007 Jul;57(1):72-8. doi: 10.1016/j.lungcan.2007.02.012. Epub 2007 Mar 27. Lung Cancer. 2007. PMID: 17391803 Clinical Trial.
A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin-gemcitabine chemotherapy (GFPC 03-01 Study).
Vergnenègre A, Tillon J, Corre R, Barlési F, Berard H, Vernejoux JM, Le Caer H, Fournel P, Marin B, Chouaïd C. Vergnenègre A, et al. Among authors: chouaid c. J Thorac Oncol. 2009 Mar;4(3):364-70. doi: 10.1097/JTO.0b013e318197f4ff. J Thorac Oncol. 2009. PMID: 19155999 Free article. Clinical Trial.
Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Vergnenegre A, Corre R, Berard H, Paillotin D, Dujon C, Robinet G, Crequit J, Bota S, Thomas P, Chouaid C; 0506 GFPC Team. Vergnenegre A, et al. Among authors: chouaid c. J Thorac Oncol. 2011 Jan;6(1):161-8. doi: 10.1097/JTO.0b013e318200f4c1. J Thorac Oncol. 2011. PMID: 21150465 Free article. Clinical Trial.
Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601).
Decroisette C, Monnet I, Berard H, Quere G, Le Caer H, Bota S, Audigier-Valette C, Geriniere L, Vernejoux JM, Chouaid C; Groupe Français de Pneumo-Cancérologie 0601 Team. Decroisette C, et al. Among authors: chouaid c. J Thorac Oncol. 2011 Mar;6(3):576-82. doi: 10.1097/JTO.0b013e318206a1e3. J Thorac Oncol. 2011. PMID: 21270669 Free article.
387 results